Immatics Biotechnologies
Pre-clinicalImmatics combines the discovery of cancer targets with T cell receptor development to create Adoptive Cell Therapies and TCR Bispecifics.
Founded
2000
Focus
Cell & Gene TherapyVaccines
About
Immatics combines the discovery of cancer targets with T cell receptor development to create Adoptive Cell Therapies and TCR Bispecifics.
Funding History
5Total raised: $363M
PIPE$75MUndisclosedFeb 15, 2021
IPO$100MUndisclosedJul 2, 2020
Series C$110MWellington PartnersJan 15, 2020
Series B$58MWellington PartnersJul 15, 2017
Company Info
TypePrivate
Founded2000
LocationTübingen, Germany
StagePre-clinical
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile